In patients with impaired sensory discrimination, pain descriptors, localization, and pain triggers are often vague or poorly defined.
Clinically and statistically significant reductions in peripheral neuropathy were seen following neurofeedback.
Patients who received concomitant NeP medications showed little difference in therapeutic response in comparison to those who received pregabalin alone.
Significant improvement were observed for sensitivity, depression, and anxiety, among others.
Patients with fibromyalgia had a high prevalence of TRAb positivity compared with control populations in previous studies.
Recent findings offer a new avenue for the development of peripheral analgesics with minimal adverse effects.
Patients with cancer or an autoimmune disease who underwent surgery were at a greater risk.
Diabetes, waist circumference, and prediabetes were the main metabolic factors associated with neuropathy.
Even after loss of exclusivity, pregabalin has lower health care costs than gabapentin.
The group developed the algorithm through a year-long process of reviewing relevant published data.
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- The Handoff: Your Week in Neurology News - 3/23/17